Literature DB >> 15853514

Advances in the treatment of pediatric brain tumors.

James T Rutka1, J S Kuo, M Carter, A Ray, S Ueda, T G Mainprize.   

Abstract

Brain tumors are a heterogeneous group of neoplasms with different origins, pathobiologies, treatments and prognoses. The collective contributions from the fields of neuro-oncology, neurosurgery, radiation oncology, neurology, neuropathology, neuroradiology and molecular biology have all led to significant advances in the treatment of certain brain tumors. Ideas from these fields, under the cooperative umbrella of clinical cancer trial consortia, have been tested in large-scale studies. As a result, patient survivals have increased markedly for these tumor types. Unfortunately, there are certain brain tumors in childhood, such as the diffuse intrinsic pontine glioma and atypical teratoid rhabdoid tumor, for which survival advantages have not been found. This review will discuss the current and possible future therapies of the most common pediatric brain tumors and highlight some of the novel imaging modalities that are used pre- and intraoperatively.

Entities:  

Mesh:

Year:  2004        PMID: 15853514     DOI: 10.1586/14737175.4.5.879

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  8 in total

1.  The influence of central review on outcome in malignant gliomas of the spinal cord: the CCG-945 experience.

Authors:  Eric Bouffet; Jeffrey C Allen; James M Boyett; Allen Yates; Floyd Gilles; Peter C Burger; Richard L Davis; Laurence E Becker; Ian F Pollack; Jonathan L Finlay
Journal:  J Neurosurg Pediatr       Date:  2015-12-18       Impact factor: 2.375

2.  A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro-Oncology study.

Authors:  Chae-Yong Kim; Seung-Ki Kim; Ji Hoon Phi; Min Mi Lee; In Ah Kim; Il Han Kim; Kyu-Chang Wang; Hye-Lim Jung; Mee Jeong Lee; Byung-Kyu Cho
Journal:  J Neurooncol       Date:  2010-03-23       Impact factor: 4.130

3.  MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence.

Authors:  Sujatha Venkataraman; Irina Alimova; Rong Fan; Peter Harris; Nicholas Foreman; Rajeev Vibhakar
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

4.  Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma.

Authors:  Jessica Pierson; Bruce Hostager; Rong Fan; Rajeev Vibhakar
Journal:  J Neurooncol       Date:  2008-07-08       Impact factor: 4.130

5.  K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.

Authors:  Dong-Anh Khuong-Quang; Pawel Buczkowicz; Patricia Rakopoulos; Xiao-Yang Liu; Adam M Fontebasso; Eric Bouffet; Ute Bartels; Steffen Albrecht; Jeremy Schwartzentruber; Louis Letourneau; Mathieu Bourgey; Guillaume Bourque; Alexandre Montpetit; Genevieve Bourret; Pierre Lepage; Adam Fleming; Peter Lichter; Marcel Kool; Andreas von Deimling; Dominik Sturm; Andrey Korshunov; Damien Faury; David T Jones; Jacek Majewski; Stefan M Pfister; Nada Jabado; Cynthia Hawkins
Journal:  Acta Neuropathol       Date:  2012-06-03       Impact factor: 17.088

6.  Extra-axial medulloblastoma in the cerebellopontine angle: Report of a rare entity with review of literature.

Authors:  Ishita Pant; Sujata Chaturvedi; Vinod K S Gautam; Pranjal Pandey; Rima Kumari
Journal:  J Pediatr Neurosci       Date:  2016 Oct-Dec

7.  Institutional experience of paediatric high-grade central nervous system tumours: an analysis of 74 patients and review of the literature.

Authors:  Faruk Guclu Pinarli; Aynur Oguz; Ceyda Karadeniz; Arzu Okur; Avni Sarac; Kemali Baykaner; Huseyin Bora; Aylar Poyraz
Journal:  Contemp Oncol (Pozn)       Date:  2012-02-29

8.  Medulloblastoma in the cerebellopontine angle mimicking a schwannoma.

Authors:  Le Thanh Dung; Nguyen Minh Duc
Journal:  Clin Case Rep       Date:  2021-02-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.